Physiomics Raises £600,000 Via Retail Offer and Placing to Support Growth

Physiomics ( (GB:PYC) ) just unveiled an announcement.

Physiomics plc, a UK AIM-listed specialist in modelling, simulation and data-driven decision support for drug development and personalised medicine, provides computational tools and bespoke models that help streamline discovery, pre-clinical and clinical programmes for leading biotech and pharma companies. Its Virtual Tumour platform and wider analytics capabilities underpin a commercial track record across more than 140 projects and over 125 targets and drugs.

The company has completed a WRAP Retail Offer raising £110,000 through the issue of 27,500,000 new shares at £0.004, alongside a previously announced placing of £490,000, bringing total gross proceeds of the fundraise to £600,000, subject only to admission to AIM. Following expected admission of the new shares on 20 March 2026, Physiomics’ enlarged issued share capital will rise to 453,208,718 ordinary shares, increasing its free float and providing additional capital to support operations and growth initiatives while altering voting rights calculations for existing shareholders.

The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.40 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.

Spark’s Take on PYC Stock

According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.

To see Spark’s full report on PYC stock, click here.

More about Physiomics

Physiomics plc is a UK-based mathematical modelling, data science and biostatistics firm that supports the development of new therapeutics and personalised medicine solutions for biotech and pharmaceutical clients. Leveraging proprietary tools such as its Virtual Tumour technology, the company has worked on more than 140 commercial projects, modelling over 125 targets and drugs for clients including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.

Average Trading Volume: 7,648,088

Technical Sentiment Signal: Sell

Current Market Cap: £1.29M

See more insights into PYC stock on TipRanks’ Stock Analysis page.